EPCT-08. ACTIVITY OF LAROTRECTINIB IN PEDIATRIC TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

BACKGROUND: TRK fusions are oncogenic drivers in a variety of tumors, many involving the CNS. Larotrectinib, a selective FDA- and EMA-approved TRK inhibitor, demonstrated a 79% objective response rate (ORR) and a 35.2-month median duration of response (DoR) in adult and pediatric patients with vario...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Goto, Hiroaki, Geoerger, Birgit, DuBois, Steven G, Grilley-Olson, Juneko E, van Tilburg, Cornelis M, Schulte, Johannes, Kang, Hyoung Jin, Tahara, Makoto, Boni, Valentina, Perreault, Sebastien, Capra, Michael, Reeves, John A, Brega, Nicoletta, Childs, Barrett H, Laetsch, Theodore W, Ziegler, David S, Doz, François
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Early Phase Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715507/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.132
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados